Category: Stock Market

The Kazia Therapeutics Ltd (ASX: KZA) share price has today smashed its 52-week high on news that the United States Food and Drug Administration (FDA) has awarded a grant for Kazia’s flagship drug. The oncology-focused biotech company has gained 46.83% and is currently trading at 82 cents.

What does Kazia do?

Kazia is an Australian oncology company that develops innovative, high impact drugs for cancer. Its lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

The company is dual listed and also trades on the Nasdaq, with its headquarters in Sydney, Australia. Kazia collaborates with leading scientists, clinicians, and investors around the world to further its products.

Kazia has stated that while there is some early stage evidence that one of its drugs may have a role to play in coronavirus infections, they do not intend to divert focus away from their core work in oncology. Kazia has advised that COVID-19 has not had an impact on any of its operations, including ongoing clinical trials.

New grant

It was announced this morning that the FDA has awarded rare pediatric disease designation (RPDD) to Kazia’s flagship drug paxalisib. It will be used for the treatment of diffuse intrinsic pontine glioma, a rare and highly-aggressive childhood brain cancer. This is a great step forward for the company as with RDPP granted, Kazia may now be eligible to receive a rare pediatric disease priority review voucher (PRV), which bodes well for the Kazia Therapeutics share price.

A PRV grants the holder an expedited 6-month review of a new drug application by the FDA. PRVs can be sold to other companies and have historically commanded prices between US$68 million and US$350 million. The designation was awarded following positive emerging preclinical data in patients with the disease.

Shareholders will be eagerly awaiting the initial clinical efficacy data that is expected in the first half of FY21. Positive clinical data may substantially enhance the likelihood of a potential future PRV.

Foolish takeaway

The news is excellent for Kazia shareholders, with the Kazia Therapeutics share price today smashing its 52-week high to hit $1 in intraday trade. 

Nevertheless, while this is good news there is still a lot of work before the drug is market ready and can generate meaningful profits.

The Kazia Therapeutics share price currently sits at 82 cents, giving the company a market capitalisation of $77.57 million.

More reading

• 2 of the best ASX shares to buy right now
• 3 ASX shares poised for huge growth over the next year
• Why the Coca-Cola share price and these ASX stocks just got upgraded by brokers to “buy”
• Why the Senex Energy share price climbed 17% in July
• 3 outstanding ASX shares to buy in August

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Kazia Therapeutics share price soars 46% on new drug grant appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/30CrfYa

If you’re looking for investment ideas, then I think the mid cap side of the market is a great place to start. This is because I believe there are a number of companies that have the potential to grow at a strong rate over the next decade and provide market-beating returns for investors.

Two top mid cap ASX shares to consider are listed below. Here’s why I like them:

Megaport Ltd (ASX: MP1)

The first mid cap ASX share to look at is Megaport. It is an elasticity connectivity and network services company. This service allows its customers to increase and decrease their available bandwidth in response to their own demand requirements. This means that users can consume the bandwidth they need when they need it, rather than be tied to fixed service levels on long-term and expensive contracts. Demand has been exceptionally strong for Megaport’s services this year, thanks to the accelerating shift to the cloud. The good news is that more and more computer infrastructure is expected to go from local servers to cloud providers like Microsoft’s Azure, Amazon’s AWS, and Google Cloud in the future. I believe Megaport is well-placed to benefit from this trend.

Pro Medicus Limited (ASX: PME)

Another mid cap ASX share that I think investors should consider is Pro Medicus. It is a leading provider of a full range of radiology IT software and services to hospitals, imaging centres, and healthcare groups worldwide. One key product in its portfolio is the Visage 7 Enterprise Imaging Platform. Management notes that it enables imaging organisations to do things they have always wanted to do, but never could. It offers immediate differentiation for imaging organisations seeking to leapfrog the status quo of commoditised legacy PACS. Given the quality of its products and its sizeable market opportunity, I believe Pro Medicus is capable of growing its earnings at an above average rate over the next decade.

More reading

• ASX 200 down 1.15%: NAB downgraded, Telstra asset sale, gold miners rocket
• 3 ASX shares I’d buy if the ASX crashes again
• 3 quality ASX tech shares to buy in August
• If you invested $50k in these ASX shares 3 years ago, you’d be a millionaire today
• Here’s how to start investing with $5k

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends MEGAPORT FPO. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended MEGAPORT FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why I would buy Megaport and this exciting mid cap ASX share appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3fBUbn2

I received a question from one of our members the other day.

It went something like:

“We stuck in there when markets fell. We’ve ridden the partial recovery. But everyone is saying the markets are going to crash hard next. When do we sell?”

I saw another headline the other day, from someone predicting an 80% stock market crash.

Frankly, because I’m greedy, I’d welcome such a crash. I mean the chance to buy a small part of Australia’s best businesses, at 20c on the dollar, because of a short-term market overreaction?

Sign me up.

And while I’m at it, I’ll be mortgaging the house, selling the cars and hocking the TV to raise as much cash as I can.

Not everyone has the same response, however.

An 80% fall would see many people sell in a fit of panic. The desperation to do something – anything – to make the pain stop would be too great.

It’s a strange quirk of human nature: When shares go up, there must be a crash around the corner. But when they fall, things are going to keep getting worse.

Man, talk about seeing the bad side of everything.

I mean, what are the odds that the ASX, currently at 6,000 points, would be not worth buying at 5,000, 4,000 or 3,000 points?

Do you really think Woolworths Group Ltd (ASX: WOW), BHP Group Ltd (ASX: BHP), CSL Limited (ASX: CSL) and Telstra Corporation Ltd (ASX: TLS), which investors happily hold at current prices, are worth holding today, but should be mindlessly sold if their prices halved?

And if they fell 80%?

I hope, dear Fool, that you’d be filling your boots.

Oh, sure. I get it.

We’d all like to sell at the very top, then buy in again at the very bottom.

I’d also like to believe in the Tooth Fairy, Santa Claus, and that Donald Trump actually understands the graphs he used in his interview this week.

Instead, though, we’re stuck in this messy, imprecise reality.

The one that, sans crystal balls, doesn’t give up its secrets – especially about the future.

So let’s break it down.

First, people have been predicting 80% falls for decades.

Yes, decades. 

Often the same people. Sometimes different ones, but with the same schtick.

So far, they’ve all been wrong. Oh, and in the meantime, the stock market is up about 18-fold over the past thirty years.

That’s a helluva gain to miss out on while you waited for the ‘predictions’ to come true, huh?

Second, 80% falls are, well, exceedingly rare. 

Third, if everyone knew the market was going to fall 80%, they’d have already sold.

Now, it’s possible that only you and I know the market is going to fall, because we’re possessed of some special insight. That only the three of us – you, me and the bloke (it’s always a bloke) who made the forecast – know the truth.

Which is as it may be… but that means not everyone knows, after all.

Fourth, your brain is messing with you. So is mine. We hear, see and read the one prediction of doom, compared to the dozens and dozens of people who expect something between a tough ride and prosperity, and which one sticks in our minds? Yep, that one guy.

The one nagging thought, snagged somewhere at the front of our consciousness while the others float by, unremarked upon.

“What if he’s right,” you think. “I mean, it’s possible.”

So ask yourself: Did you think “What if he’s right?” after someone else predicted a swift recovery? Or a prolonged period of stagnation, then recovery?

Probably not. We don’t tend to hang on to those thoughts. It’s the predictions of doom that preoccupy us.

And it’s not your fault.

It’s evolution.

Our brains just aren’t programmed to think that far ahead. 

Or to think in compound, exponential terms.

Confronted with decades of compound growth (including many periods of tough times), we don’t think “What if that continues?”, but rather “What if it ends?”.

And fair enough.

You won’t get any blame from me.

But what I will do is invite you to engage the part of our brain that can critically analyse our instinctive responses.

We instinctively fear the dark, even though we know there’s nothing there.

We instinctively jump at loud noises, even though we know the cause is almost certainly benign.

We instinctively mistrust people who are unlike us, even though we know it’s an evolutionary leftover.

And yes, we instinctively fear market falls, even though we know the overwhelming story of the past century (and more) is that, despite the occasional fall, stock markets tend to go higher.

(And if your response to that is “Yeah, but what about…?”, I’ll tell you that I understand that response, but you’re likely grabbing for the exception that proves the rule, not something that renders the rule useless.)

For what it’s worth, I think an 80% fall is remarkably unlikely.

But far more importantly, it it happens, either one of two things will be true:

The economy has permanently collapsed, and your dollars will be as useless as your shares (and gold, and bitcoin); or

It’s a short term overreaction, which either presents a buying opportunity, or is just a tough time to live through, while you wait for sanity to return.

(And remember, you shouldn’t be investing any money you need in the next 3-5 years, anyway.)

If Woolies falls 80%, do you really think the company will be serving 80% fewer Australians or making 80% less profit from here until eternity?

Do you think CSL sells 80% fewer vaccines and blood products, forever?

Does ResMed Inc (ASX: RMD) lose 80% of its sleep apnoea market?

Will Telstra be only one-fifth of its current size, permanently?

Now, ‘predictions’ of an 80% fall make for great headlines. They get tongues wagging, and people worrying.

Remember last year’s ‘prediction’ of a 50% fall in house prices?

Or 2016’s forecast of an 80% fall in the share market (sounds familiar, huh?).

Every single prediction of a cataclysmic market crash since 1932 has been wrong.

Every. Single. One.

No, I can’t rule it out. Unlike those people who make their outlandish predictions, I make no silly promises.

Is it possible? Yep.

But there are plenty of things that are far more likely that we simply outright ignore in our daily lives, because they’re neither so stark, so seemingly dangerous or so breathlessly reported.

If I declared myself a weatherman, and told you there was a flash flood coming, you’d want to see both my credentials and my track record, right?

I’d suggest treating those predictions with the same disdain.

Fool on!

More reading

• The latest ASX 200 stocks downgraded by top brokers
• Is the ResMed share price a buy?
• Why I would buy and hold CSL shares today
• Brokers name 3 ASX shares to buy right now
• ASX 200 down 0.45%: REA Group impresses, IAG profit slump, ResMed downgraded

Scott Phillips owns shares of Telstra Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Telstra Limited. The Motley Fool Australia owns shares of Woolworths Limited. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Ready for the “80% stock market crash”? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/31wHFjM

Are you looking for safe dividend options during these uncertain times? Then you might want to consider buying the ASX dividend shares listed below.

I feel confident that they will continue to pay dividends largely as normal for the foreseeable future. Here’s why I would buy them:

Vanguard Australian Shares High Yield ETF (ASX: VHY)

The first dividend option for investors to consider buying is this exchange traded fund. As you might have guessed from its name, the Vanguard Australian Shares High Yield ETF has a focus on high yield shares. The fund has invested in 66 of the highest yielding blue chip shares on the Australian share market.

This includes the likes of BHP Group Ltd (ASX: BHP), the big four banks, Coles Group Ltd (ASX: COL), and telco giant Telstra Corporation Ltd (ASX: TLS). While predicting what dividend it will pay next year is tricky, based on the shares within the fund, I would expect an FY 2021 dividend yield somewhere in the region of 4% to 5%. Another positive with this fund is the diversity it offers investors. No industry accounts for more than 40% of the fund and no single company accounts for more than 10%.

Wesfarmers Ltd (ASX: WES)

A final dividend share to consider buying is Wesfarmers. I think the conglomerate is a great option for income investors due to the quality and diversity of its portfolio. Another positive is management’s long track record of making earnings accretive acquisitions. This could come into play in the near future given the sizeable amount of cash sitting on its balance sheet following the sell down of its stake in supermarket giant Coles earlier this year.

All in all, I believe the conglomerate is well-positioned to deliver solid earnings and dividend growth over the next decade. And based on the current Wesfarmers share price, I estimate that it provides investors with an FY 2021 fully franked ~3.2% dividend yield.

More reading

• Nick Scali share price bolstered by strong outlook and dividend upgrade
• 5 things to watch on the ASX 200 on Wednesday
• ASX 200 jumps 2% higher, Afterpay soars
• Looking for good ASX dividend shares? I would buy these right now
• How will Victoria’s stage 4 lockdowns impact ASX shares?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Telstra Limited. The Motley Fool Australia owns shares of COLESGROUP DEF SET and Wesfarmers Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post 2 safe ASX dividend shares to buy in uncertain times appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2XB8n9I

The listed investment companies (LICs) of Future Generation Investment Company Ltd (ASX: FGX) and Future Generation Global Invstmnt Co Ltd (ASX: FGG) have grown their dividends in the June 2020 results.

The Future Generation companies are LICs with two main goals. The first goal is to donate 1% of net assets each year to youth charities and youth mental health charities. They can do this by charging shareholders no management fees. The fund managers that the LICs invests with also don’t charge management fees – they work for free. The other goal is to generate returns for shareholders. 

Future Generation Australia HY20 result

Future Generation Australia reported that over the six months to 30 June 2020, its portfolio’s decline of 7.1% outperformed the S&P/ASX All Ordinaries Accumulation Index by 3.3% (the index dropped 10.4%) which included the COVID-19 crash.

Over the past 12 months the LIC’s negative 1.2% return outperformed the index by 6%. Since inception the Future Generation Australia portfolio has grown by an average of 7.3% per annum, outperforming the index by 1.8% per annum. The outperformance was delivered with less volatility.

The board decided to increase its interim dividend by 8.3% to 2.6 cents per share. The LIC had an estimated profit reserve of 8.6 cents per share at 30 June 2020. The LIC was able to fund this dividend announcement thanks to the profit reserve. The Future Generation share price is up almost 3% in reaction to the announcement.

At the current Future Generation Australia share price of $1.05, it offers a fully franked dividend yield of 5% or 7% when grossed-up to include the franking credits.

Some of the charities currently supported include: Act For Kids, Australian Children’s Music Foundation, Australian Indigenous Education Foundation, DEBRA Australia, Diabetes Kids Fund, Giant Steps, Lighthouse Foundation, Mirabel Foundation, Raise Foundation, United Way Australia, Variety and Youth Off The Streets.

This year the LIC will invest $4.8 million into charities, which will bring the total charitable donations since inception to $21.4 million.

At the current Future Generation Australia share price it’s trading at a 8.5% discount to the net tangible assets (NTA) at 30 June 2020.

Future Generation Global HY20 result

Future Generation Global reported that its portfolio’s return of 0.3% outperformed the MSCI AC World Index’s (AUD) return of negative 4.4% by 4.7%. Over the past year the global LIC’s 7.5% portfolio return outperformed the index by 3.6%.

The leadership was pleased to preserve shareholder capital in a highly volatile period.

Since inception, the LIC’s average portfolio return per annum of 9.2% was 0.3% per annum better than the index.

The board of Future Generation Global announced a 33% increase to its dividend to 2 cents per share. This was achieved by tapping into the profit reserve as well as the solid outperformance achieved in recent times.

The Future Generation Global share price is up almost 1% in reaction to the announcement.

If the LIC were to pay 2 cents per share every 12 months going forwards, it would have a grossed-up dividend yield of 2.3% based on the current Future Generation Global share price.

Some of the current youth mental charities currently supported are: Black Dog Institute, Brain and Mind Centre, Butterfly Foundation for Eating Disorders, Kids Helpline, Orygen – the National Centre of Excellence in Youth Mental Health, ReachOut Australia, SANE Australia and Youth Focus.

This year the global LIC will invest $5.7 million, which will bring total donations since inception to $19.7 million.

At the current Future Generation Global share price it’s trading at a 17% discount to the June 2020 NTA.

Foolish takeaway

The share prices of both LICs have risen in reaction this result. Outperformance and an increased dividend have been welcomed in these difficult times and investors clearly thought that both were opportunities after today’s result announcements. 

More reading

• 3 ASX LICs offering big dividend yields over 7%
• This ASX share could be perfect for a $500 buy
• 3 ASX shares I’d buy to quickly add diversification
• 3 top ASX dividend shares for income investors in August
• 3 of the best ASX dividend shares for income

The post Future Generation LICs grow dividends in June result appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2F0K9zt

The market looks set to end the week on a negative note, but some ASX stocks are feeling more heat after being downgraded by leading brokers.

The S&P/ASX 200 Index (Index:^AXJO) shed 0.7% of its value to trade just under the psychologically important 6,000 mark.

However, the top 200 benchmark is still finish the week with a more than 1% gain, although the same can’t be said for the RESMED/IDR UNRESTR (ASX: RMD) share price.

ResMed’s double downgrad

Shares in the sleep disorder treatment company tumbled 3.1% to $25.08 in after lunch trade. This makes it the third worst performer on the ASX 200 after the JANUS/IDR UNRESTR (ASX: JHG) share price and V MONEY UK/IDR UNRESTR (ASX: VUK) share price.

ResMed is losing favour today as not one, but two brokers downgraded their recommendation on the stock following its profit results.

While ResMed’s earnings came in ahead of consensus, the good news is reflected in its share price, according to Morgan Stanley.

Earnings beat fails to excite

The company’s earnings beat is largely driven by better-than-expected cost control and demand for ventilators to treat severe COVID-19 cases.

These tailwinds are likely to fade with the broker pointing to an acceleration in cost growth as the economy picks up speed. Further, demand for ventilators will also taper off in FY21.

The fall-off in ventilator sales will need to be made up by rising demand for its core sleep apnea solutions.

Slower recovery for core business

“The main challenge now is to weigh up what looks likely to be a sharp tapering of ventilator demand (10-15% of Group) against a steady recovery in sleep apnea (85-90%) through the coming quarters, which is clearly subject to a wide degree of uncertainty,” said Goldman Sachs.

The fact is the pace of growth for its core products is unlikely to make up for falling ventilator sales.

Morgan Stanley cut its recommendation to “equal-weight” from “overweight” with a price target of $25.40 a share.

Goldman lowered its rating on ResMed to “neutral” from “buy” with a target price of $26.40 a share.

Hanging up on TPG

Another stock that’s underperforming today is the TPG Telecom Ltd (ASX: TPG) share price, which got downgraded by UBS to “sell” from “neutral”.

The broker believes that the special dividend of $0.49 a share and the Tuas Ltd (AS: TUA) spin-off haven’t been unwound from the current share price.

“On the day prior to the announcement of the special dividend, TPG was trading at $8.05, and rallied to $8.90 immediately prior to the completion of the merger,” said UBS.

“This compares with our previous $8.00 valuation. Our new valuation is $7.20, which removes the special dividend and Tuas.”

Too big a premium to Telstra

Further, UBS pointed out that TPG trades at a premium to the Telstra Corporation Ltd (ASX: TLS) share price.

While some premium may be justified due to synergies from TPG’s merger with Vodafone, UBS thinks it’s currently too excessive.

More reading

• Ready for the “80% stock market crash”?
• Is the ResMed share price a buy?
• Mesoblast’s share price gained another 16% in July. Here’s why.
• Why I would buy and hold CSL shares today
• Brokers name 3 ASX shares to buy right now

Motley Fool contributor Brendon Lau owns shares of Telstra Limited and TPG Telecom Ltd. The Motley Fool Australia owns shares of and has recommended Telstra Limited. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post The latest ASX 200 stocks downgraded by top brokers appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3igt2b5

The Troy Resources Ltd (ASX: TRY) share price is rocketing higher today, after the miner released an exploration update regarding its gold project in Guyana. The Troy Resources share price is currently trading 23.81% higher up to 13 cents.

What does Troy Resources do?

Troy Resources is a small- to mid-size gold producer with a history of developing and operating mines in Australia and South America.

Troy has been operating in South America since 2002. In July 2013, the company acquired Azimuth Resources which had discovered and delineated the Karouni Project in Guyana. Troy Resources fast tracked development of Karouni, with first gold production occurring in November 2015.

Exploration update

This morning, Troy Resources provided the ASX with reports indicating strong gold finds at its Karouni project in Guyana. This comes after new tailwinds have been pushing gold prices closer to record highs.

Troy recently commenced an 8 hole diamond drilling campaign at Smarts Underground (one of its mines in Guyana) targeting mineralisation beneath the Smarts Pits. The first 4 drill holes demonstrated strong finds and this 5th hole demonstrates more of the same.

Some of the highlights from the results are:

• 2 metres @ 31.38 grams per tonne (g/t Au) from 175 metres
• 6 metres @ 8.12 g/t Au from 196 metres
• 2 metres @ 26.38 g/t Au from 211 metres
• 2 metres @ 15.68 g/t Au from 291 metres
• 26 metres @ 3.58 g/t Au from 305 metres
• 10 metres @ 10.69 g/t Au from 384 metres

The second stage of the drilling campaign, featuring an additional 3 holes (though this number may be increased), will commence shortly, with completion anticipated in September.

What now for the Troy Resources share price

As mentioned above, gold prices have been soaring recently, smashing through the US$2,000 an ounce target. With some reports suggesting that gold could continue its run, now is a good time to be a gold miner.

However, some experts have been arguing that gold may be just as likely to witness a painful correction, which wouldn’t bode well for the Troy Resources share price.

At the time of writing, the Troy Resources share price is up 8.33% on this time last year, and 44.44% year to date.

More reading

• Ready for the “80% stock market crash”?
• 2 safe ASX dividend shares to buy in uncertain times
• Future Generation LICs grow dividends in June result
• The latest ASX 200 stocks downgraded by top brokers
• Is the ResMed share price a buy?

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why has the Troy Resources share price blasted 23% higher today? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/30AR0bi

The ResMed Inc (ASX: RMD) share price was down more than 14% for the week after hitting an intra-day low of $24.18 earlier today. Despite the volatile price action, the ResMed share price could be a long-term buy after the company reported strong full-year results.

How did ResMed perform?

The company released its fourth quarter and full-year update yesterday, which saw the RedMed share price sell-off sharply. Despite the negative price action, ResMed reported a very strong set of results.

For the three months ending 30 June 2020, ResMed reported a 10% increase in revenue on a constant currency basis of US$770.3 million. In addition to the robust revenue growth, the company also reported strong earnings with gross margins surging 59.9% for the period. As a result, ResMed saw a quarterly operating profit of US$243.4 million with quarterly net income surging 40% to US$193.3 million,

For the full-year, ResMed reported a 15% increase in revenue of US$3 billion on a constant currency basis and a 24% increase in operating profit of US$890.9 million. The company’s management noted that the strong performance reflects the strength and resilience of ResMed given the uncertain trading environment. Clearly, however, these results were not enough to prevent the negative impact on the ResMed share price.

What has fuelled ResMed’s performance?

ResMed is a global leader in respiratory medical devices, particularly targeted towards the treatment of sleep apnoea. In addition, the company also produces invasive and non-invasive ventilators that are used to boost the oxygen intake of patients. 

In its report, ResMed revealed that the company had produced 150,000 ventilators in the six months through to 30 June to help countries fight the COVID-19 pandemic. More than 52,000 of these units were for an urgent contract from the Australian Government, as the company tripled its ventilator production in order to meet demand.

Should you buy at today’s ResMed share price?

Many investors were highly anticipating ResMed’s results, given the demand for the company’s products during the pandemic. However, despite the bumper results, the ResMed share price tanked more than 8% yesterday. I believe the sell-off was a result of the company flagging a slow recovery in its core sleep apnoea business, with single digit growth expected to continue for the next 12 months.

The ResMed share price continued its fall this morning, plunging as low as $24.18 before bouncing back to its current level of $25.01 at the time of writing. Given the uncertain nature of the pandemic, and the further treatments that could be necessitated by it, I believe ResMed’s products could continue to see unprecedented demand over the long-term.

However, in my opinion, there shouldn’t be a mad rush to buy shares in the company at today’s ResMed share price. I think a conservative, long-term strategy would be to wait for investors to fully-digest the company’s results and let the ResMed share price consolidate further before buying in.

More reading

• Ready for the “80% stock market crash”?
• The latest ASX 200 stocks downgraded by top brokers
• Brokers name 3 ASX shares to buy right now
• ASX 200 down 0.45%: REA Group impresses, IAG profit slump, ResMed downgraded
• Why Australian Ethical, Northern Star, ResMed, & TPG Telecom are dropping lower

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Is the ResMed share price a buy? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3kgYKHj

If you have $2,000 sitting in a savings account, I would suggest you consider investing it into the share market.

After all, the potential returns on offer are vastly superior to the extremely low interest rates of 0.05% provided with savings accounts right now.

But where should you invest these funds? Here are two ASX shares that I would invest $2,000 into:

Afterpay Ltd (ASX: APT)

I think this payments giant could be a great option for that $2,000 investment. Although its shares have been on fire this year, I don’t believe it is too late to invest if you’re planning to make a long term investment in the company. This is because I feel confident the buy now pay later provider is well-positioned to become a payments giant thanks to the growing popularity of its platform with consumers and merchants and its global expansion opportunity.

In respect to the latter, Afterpay is launching into Canada shortly. After which, I suspect mainland Europe will be targeted and maybe even the Chinese market in the future. Especially after WeChat owner Tencent Holdings became a substantial holder a few months ago.

Nanosonics Ltd (ASX: NAN)

Another option for investors to consider investing $2,000 into is this infection prevention specialist. It is the company behind the industry-leading trophon EPR disinfection system for ultrasound probes. Although FY 2020 might underwhelm because of the pandemic, I expect this product and the growing recurring revenues it generates to underpin solid earnings growth during the 2020s.  

This should be supported by the upcoming launch of several new products which are targeting unmet needs. Not a lot is known about these secretive products. However, the first one is understood to have a market opportunity of a similar size to the trophon EPR product. Given that this effectively doubles its total addressable market, if it is a success then Nanosonics’ growth could be given a significant boost.

More reading

• Tech shares drive rally as new research indicates BNPL share prices lofty
• Sezzle share price leaps 10% on oversubscribed share purchase plan
• Why these ASX tech shares are skyrocketing
• Top broker warns Afterpay and these ASX stocks could disappoint on profit results
• 3 stellar mid cap ASX shares to buy

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Nanosonics Limited. The Motley Fool Australia owns shares of AFTERPAY T FPO. The Motley Fool Australia has recommended Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post 2 explosive ASX shares to buy with $2,000 today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3a22sQa